Among them, SGLT1 and SGLT2, encoded by the genes SLC5A1 and SLC5A2, are the most studied due to their known association with congenital glucose–galactose malabsorption and familial renal glycosuria, respectively, when they are defective [38,39], and to their recent role as therapeutic targets for treating T2DM. This evidence concerns the gene SLC5A2 and renal glycosuria.